{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:27:34Z","timestamp":1787668054154,"version":"build-2736575974"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Benign prostatic hyperplasia (BPH) is a common age-related disorder characterized by progressive prostatic enlargement and lower urinary tract symptoms, yet current medical therapies remain constrained by delayed onset, incomplete efficacy, and treatment-related adverse effects. Resveratrol (Res), a naturally occurring polyphenol, has emerged as a promising candidate for BPH intervention because its pharmacological profile aligns closely with the multifactorial biology of the disease. This review synthesizes current evidence showing that Res may counteract BPH progression through coordinated regulation of several interconnected processes, including abnormal prostate cell proliferation, apoptosis resistance, oxidative stress, chronic inflammation, fibrotic remodeling, and androgen-related signaling. Rather than acting on a single target, Res appears to reshape the pro-hyperplastic microenvironment at multiple levels, providing a mechanistic rationale for its therapeutic potential. However, the available evidence remains predominantly preclinical, and its clinical translation is still limited by poor oral bioavailability, extensive first-pass metabolism, uncertainty regarding the active molecular species in prostate tissue, and the lack of standardized formulations and robust clinical trials. Overall, Res represents a biologically plausible but not yet clinically established strategy for BPH management.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1874552","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:44:15Z","timestamp":1787665455000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Resveratrol in benign prostatic hyperplasia: mechanistic insights and therapeutic perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Bailong","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Urology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Sichuan, Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Sichuan, Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Sichuan, Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaodong","family":"You","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Sichuan, Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, People\u2019s Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine","place":["Deyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinze","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, People\u2019s Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine","place":["Deyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Sichuan, Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/nrdp.2016.31","article-title":"Benign prostatic hyperplasia","volume":"2","author":"Chughtai","year":"2016","journal-title":"Nat Rev Dis Primer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002184","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part II\u2014surgical evaluation and treatment","volume":"206","author":"Lerner","year":"2021","journal-title":"J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2025.2478875","article-title":"National prevalence and incidence of benign prostatic hyperplasia\/lower urinary tract symptoms and validated risk factors pattern","volume":"28","author":"Lin","year":"2025","journal-title":"Aging Male"},{"key":"B4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12894-025-01715-9","article-title":"Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035","volume":"25","author":"Wei","year":"2025","journal-title":"BMC Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023","volume":"211","author":"Sandhu","year":"2024","journal-title":"J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.006","article-title":"Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: Population-based cohort study","volume":"68","author":"Cindolo","year":"2015","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.16438\/j.0513-4870.2020-0745","article-title":"Advances in the structural modification and biological activity of resveratrol","volume":"55","author":"Li","year":"2020","journal-title":"Acta Pharm Sin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.prenap.2024.100047","article-title":"Resveratrol: A comprehensive review of its multifaceted health benefits, mechanisms of action, and potential therapeutic applications in chronic disease","volume":"3","author":"Vikal","year":"2024","journal-title":"Pharmacol Res - Nat Prod"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.075","article-title":"Resveratrol: From enhanced biosynthesis and bioavailability to multitargeting chronic diseases","volume":"109","author":"Pannu","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15229","article-title":"Benign prostatic hyperplasia \u2013 what do we know","volume":"127","author":"Devlin","year":"2021","journal-title":"BJU Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2007.09.012","article-title":"Inflammation and benign prostatic hyperplasia","volume":"35","author":"Nickel","year":"2008","journal-title":"Urol Clin North Am"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15518","article-title":"Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options","volume":"31","author":"Inamura","year":"2024","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bju.12728","article-title":"Metabolic syndrome and benign prostatic enlargement: A systematic review and meta-analysis","volume":"115","author":"Gacci","year":"2015","journal-title":"BJU Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10522-025-10226-x","article-title":"Exploring TGF-\u03b2 signaling in benign prostatic hyperplasia: From cellular senescence to fibrosis and therapeutic implications","volume":"26","author":"Khan","year":"2025","journal-title":"Biogerontology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158357","article-title":"Resveratrol-mediated repression and reversion of prostatic myofibroblast phenoconversion","volume":"11","author":"Gharaee-Kermani","year":"2016","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157165","article-title":"Elucidating the therapeutic mechanisms of resveratrol in benign prostatic hyperplasia via an integrated strategy of network pharmacology, multi-omics and molecular biology","volume":"147","author":"Li","year":"2025","journal-title":"Phytomedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41698-017-0038-6","article-title":"The therapeutic potential of resveratrol: A review of clinical trials","volume":"1","author":"Berman","year":"2017","journal-title":"NPJ Precis Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jsfa.10152","article-title":"Resveratrol: A review of plant sources, synthesis, stability, modification and food application","volume":"100","author":"Tian","year":"2020","journal-title":"J Sci Food Agric"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000885","article-title":"High absorption but very low bioavailability of oral resveratrol in humans","volume":"32","author":"Walle","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","article-title":"Bioavailability of resveratrol","volume":"1215","author":"Walle","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26144367","article-title":"A brief updated review of advances to enhance resveratrol\u2019s bioavailability","volume":"26","author":"De Vries","year":"2021","journal-title":"Molecules"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqaa414","article-title":"Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a \u201cdietary-achievable\u201d or \u201cpharmacological\u201d dose: What are the implications for anticancer activity","volume":"113","author":"Cai","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/pros.23100","article-title":"Oxidative stress promotes benign prostatic hyperplasia","volume":"76","author":"Vital","year":"2016","journal-title":"Prostate"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.focha.2023.100539","article-title":"Resveratrol as a privileged molecule with antioxidant activity","volume":"3","author":"Constantinescu","year":"2023","journal-title":"Food Chem Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmu135","article-title":"Anti-inflammatory effect of resveratrol through the suppression of NF-\u03baB and JAK\/STAT signaling pathways","volume":"47","author":"Ma","year":"2015","journal-title":"Acta Biochim Biophys Sin"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061812","article-title":"Anti-inflammatory effects of resveratrol: mechanistic insights","volume":"19","author":"Coutinho","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15576","article-title":"Proliferative mechanism of benign prostatic hyperplasia by NLRP3 inflammasome through the complement pathway","volume":"31","author":"Hata","year":"2024","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/np500810c","article-title":"Effects of resveratrol on benign prostatic hyperplasia by the regulation of inflammatory and apoptotic proteins","volume":"78","author":"Chung","year":"2015","journal-title":"J Nat Prod"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2016.01.017","article-title":"Resveratrol and the mitochondria: From triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a mechanistic view","volume":"1860","author":"de Oliveira","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12906-019-2648-8","article-title":"Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway","volume":"19","author":"Li","year":"2019","journal-title":"BMC Complement Altern Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115969","article-title":"Resveratrol attenuates the proliferation of prostatic stromal cells in benign prostatic hyperplasia by regulating cell cycle progression, apoptosis, signaling pathways, BPH markers, and NF-\u03baB activity","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8080261","article-title":"Resveratrol modulates transforming growth factor-beta (TGF-\u03b2) signaling pathway for disease therapy: A new insight into its pharmacological activities","volume":"8","author":"Ashrafizadeh","year":"2020","journal-title":"Biomedicines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34974","article-title":"Resveratrol ameliorates pathological fibrosis of the myodural bridge by regulating the SIRT3\/TGF-\u03b21\/smad pathway","volume":"10","author":"Qin","year":"2024","journal-title":"Heliyon"},{"key":"B34","article-title":"Preliminary study on the inhibitory effect of resveratrol on benign prostatic hyperplasia in rats","volume":"23","author":"Xu","year":"2009","journal-title":"Chin J Androl"},{"key":"B35","article-title":"Protective effect of resveratrol against prostate enlargement induced by high-fat diet","volume":"10","author":"Yang","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2017.12.009","article-title":"Obesity-induced mouse benign prostatic hyperplasia (BPH) is improved by treatment with resveratrol: Implication of oxidative stress, insulin sensitivity and neuronal growth factor","volume":"55","author":"Calmasini","year":"2018","journal-title":"J Nutr Biochem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.190173","article-title":"Peanut sprout extracts cultivated with fermented sawdust medium inhibits benign prostatic hyperplasia in vitro and in vivo","volume":"38","author":"Song","year":"2020","journal-title":"World J Mens Health"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.31351\/vol33iss2pp14-19","article-title":"Pterostilbene effect on inflammatory and oxidation markers in benign prostatic hyperplasia rats model","volume":"33","author":"Jawad","year":"2024","journal-title":"Iraqi J Pharm Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23006","article-title":"Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men","volume":"75","author":"Kj\u00e6r","year":"2015","journal-title":"Prostate"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.04.003","article-title":"SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function","volume":"15","author":"Price","year":"2012","journal-title":"Cell Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13020053","article-title":"Oxidative stress in benign prostatic hyperplasia: Mechanisms, clinical relevance and therapeutic perspectives","volume":"13","author":"Kaltsas","year":"2025","journal-title":"Diseases"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136516","article-title":"Urinary inflammatory and oxidative stress biomarkers as indicators for the clinical management of benign prostatic hyperplasia","volume":"26","author":"Jiang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/and.14004","article-title":"Resveratrol could attenuate prostatic inflammation in rats with oestradiol\u2010induced chronic prostatitis","volume":"53","author":"Qian","year":"2021","journal-title":"Andrologia"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600244","article-title":"Modulation of NF\u2010\u03baB\u2010dependent transcription and cell survival by the SIRT1 deacetylase","volume":"23","author":"Yeung","year":"2004","journal-title":"EMBO J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.5115\/acb.2011.44.3.194","article-title":"Resveratrol activates AMPK and suppresses LPS-induced NF-\u03baB-dependent COX-2 activation in RAW 264.7 macrophage cells","volume":"44","author":"Yi","year":"2011","journal-title":"Anat Cell Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117362","article-title":"Resveratrol protects against CIH-induced myocardial injury by targeting Nrf2 and blocking NLRP3 inflammasome activation","volume":"245","author":"Sun","year":"2020","journal-title":"Life Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24903","article-title":"Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy","volume":"230","author":"Chang","year":"2015","journal-title":"J Cell Physiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-1169","article-title":"LncRNA DIO3OS regulated by TGF-\u03b21 and resveratrol enhances epithelial mesenchymal transition of benign prostatic hyperplasia epithelial cells and proliferation of prostate stromal cells","volume":"10","author":"Chen","year":"2021","journal-title":"Transl Androl Urol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.CAN-08-2146","article-title":"Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-\u03b2","volume":"69","author":"Rahimi","year":"2009","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M800902200","article-title":"AMP-activated protein kinase inhibits transforming growth factor-\u03b2-induced Smad3-dependent transcription and myofibroblast transdifferentiation","volume":"283","author":"Mishra","year":"2008","journal-title":"J Biol Chem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/art.39061","article-title":"The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor \u03b2 signaling","volume":"67","author":"Wei","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205740","article-title":"Sirt1 regulates canonical TGF-\u03b2 signalling to control fibroblast activation and tissue fibrosis","volume":"75","author":"Zerr","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7960","article-title":"Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis by mast cell suppression","volume":"17","author":"Zeng","year":"2018","journal-title":"Mol Med Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.44443","article-title":"Resveratrol reduces inflammation-related prostate fibrosis","volume":"17","author":"Vicari","year":"2020","journal-title":"Int J Med Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajur.2019.10.003","article-title":"The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review","volume":"7","author":"Vickman","year":"2020","journal-title":"Asian J Urol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3177\/jnsv.53.556","article-title":"Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells","volume":"53","author":"Harada","year":"2007","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsbmb.2010.11.002","article-title":"Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: Implication of DNA binding and acetylation of the receptor","volume":"123","author":"Harada","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1210\/me.2006-0467","article-title":"Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor","volume":"21","author":"Dai","year":"2007","journal-title":"Mol Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1997","article-title":"Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells","volume":"5","author":"Jurmeister","year":"2014","journal-title":"Oncotarget"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4472","article-title":"Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins","volume":"66","author":"Xu","year":"2006","journal-title":"Cancer Res"},{"key":"B63","article-title":"Androgen receptor-mTOR crosstalk is regulated by testosterone availability: Implication for prostate cancer cell survival","volume":"30","author":"Wu","year":"2010","journal-title":"Anticancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-11-0148","article-title":"Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases\u2014safety, pharmacokinetics, and pharmacodynamics","volume":"4","author":"Howells","year":"2011","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S37840","article-title":"Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability","volume":"8","author":"Neves","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/17425247.2014.878701","article-title":"Improved oral delivery of resveratrol using proliposomal formulation: Investigation of various factors contributing to prolonged absorption of unmetabolized resveratrol","volume":"11","author":"Basavaraj","year":"2014","journal-title":"Expert Opin Drug Delivery"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/srep15216","article-title":"Amino acid carbamates as prodrugs of resveratrol","volume":"5","author":"Mattarei","year":"2015","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1021\/jf505694e","article-title":"Zein-based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock","volume":"63","author":"Pe\u00f1alva","year":"2015","journal-title":"J Agric Food Chem"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2174206","article-title":"Recent progress in nanotechnology-based drug carriers for resveratrol delivery","volume":"30","author":"Li","year":"2023","journal-title":"Drug Delivery"},{"key":"B70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00280-010-1525-4","article-title":"Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats","volume":"68","author":"Kapetanovic","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2364","article-title":"Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis","volume":"70","author":"Brown","year":"2010","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3233\/CH-2011-1424","article-title":"Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease","volume":"50","author":"Magyar","year":"2012","journal-title":"Clin Hemorheol Microcirc"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/nu14081633","article-title":"Resveratrol inhibits metabolism and affects blood platelet function in type 2 diabetes","volume":"14","author":"Michno","year":"2022","journal-title":"Nutrients"},{"key":"B74","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3892\/etm.2016.3958","article-title":"The effect of resveratrol on hypertension: A clinical trial","volume":"13","author":"Theodotou","year":"2017","journal-title":"Exp Ther Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"31297","DOI":"10.1038\/s41598-025-17305-6","article-title":"Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients","volume":"15","author":"Shafiei","year":"2025","journal-title":"Sci Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-09-0155","article-title":"Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study","volume":"3","author":"Chow","year":"2010","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.008","article-title":"Summary paper on the 2023 european association of urology guidelines on the management of non-neurogenic male lower urinary tract symptoms","volume":"84","author":"Gravas","year":"2023","journal-title":"Eur Urol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1874552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:44:17Z","timestamp":1787665457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1874552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2026.1874552"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1874552","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1874552"}}